Antithymocyte-globulin

2021 ◽  
Vol 1863 (1) ◽  
pp. 55-55
Keyword(s):  
Antithymocyte Globulin

scholarly journals Safety and Efficacy of Indigenous Equine Antithymocyte Globulin Along with Cyclosporine in Subjects with Acquired Aplastic Anemia

2014 ◽  
Vol 31 (2) ◽  
pp. 174-179 ◽  
Author(s):  
M. B. Agarwal ◽  
Farah Jijina ◽  
Sandip Shah ◽  
Pankaj Malhotra ◽  
Sharat Damodar ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Safety And Efficacy

Antithymocyte-globulin

2021 ◽  
Vol 1837 (1) ◽  
pp. 77-77
Keyword(s):  
Antithymocyte Globulin

scholarly journals Antithymocyte globulin/methylprednisolone

2021 ◽  
Vol 1860 (1) ◽  
pp. 68-68
Keyword(s):  
Antithymocyte Globulin

Antithymocyte-globulin/mycophenolate-mofetil

2021 ◽  
Vol 1868 (1) ◽  
pp. 85-85
Keyword(s):  
Mycophenolate Mofetil ◽  
Antithymocyte Globulin

scholarly journals Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation

2021 ◽  
Author(s):  
Xi Sun ◽  
Jun Yang ◽  
Yu Cai ◽  
Liping Wan ◽  
Chongmei Huang ◽  
...  
Keyword(s):  
Antithymocyte Globulin ◽  
Low Dose ◽  
Peripheral Blood Stem Cell ◽  
Unrelated Donor ◽  
Relapse Free Survival ◽  
Matched Unrelated Donor ◽  
Free Survival ◽  
Graft Versus Host ◽  
Gvhd Prophylaxis ◽  
Blood Stem Cell Transplantation

AbstractThe standard regimens for graft-versus-host disease (GvHD) prophylaxis in matched unrelated donor (MUD) transplantation were based on antithymocyte globulin (ATG) in combination with calcineurin inhibitors (CNIs). To improve the efficiency of GvHD prophylaxis in MUD peripheral blood stem cell transplantation (MUD-PBSCT), 51 patients with hematological malignancies received a novel regimen for GvHD prophylaxis, which is composed of low dose of ATG (5 mg/kg) plus low-dose posttransplant cyclophosphamide (PTCy, 50 mg/kg) (low-dose ATG/PTCy) combined with cyclosporine A (CsA) and mycophenolate mofetil (MMF). The cumulative incidences (CIs) of grades I–IV and II–IV acute GvHD (aGvHD) were 14.5% (95% CI, 9.4–19.6%) and 6.2% (95% CI, 2.8–9.6%) within 100 days after transplantation, respectively. The CI of mild-to-moderate chronic GvHD (cGvHD) within 1 year was 11.5% (95% CI, 6.6–16.4%). The 1-year probabilities of GvHD and relapse-free survival, relapse-free survival, and over survival were 70.6% (95% CI, 64.2–77.0%), 76.5% (95% CI, 70.6–82.4%), and 82.0% (95% CI, 76.5–87.5%), respectively. The CIs of CMV and EBV reactivation by day 180 were 10.4% (95% CI, 1.5–19.4%) and 8.3% (95% CI, 0.2–16.4%), respectively. The results suggested that low-dose ATG/PTCy combined with CsA/MMF as GvHD prophylaxis in MUD-PBSCT had promising activity.

Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients

2021 ◽  
Author(s):  
Nicolas Azzopardi ◽  
Hélène Longuet ◽  
David Ternant ◽  
Gilles Thibault ◽  
Valérie Gouilleux-Gruart ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Antithymocyte Globulin ◽  
Transplant Patients ◽  
Kidney Transplant Patients

Outcomes of Adolescents and Young Adults Compared with Children with Acute Leukemia after Single-Unit Unrelated Cord Blood Transplantation Using Myeloablative Conditioning without Antithymocyte Globulin

2021 ◽  
pp. 1-11
Author(s):  
Xuhan Zhang ◽  
Huilan Liu ◽  
Changcheng Zheng ◽  
Baolin Tang ◽  
Xiaoyu Zhu ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Single Unit ◽  
Antithymocyte Globulin ◽  
Immune Reconstitution ◽  
Cord Blood Transplantation ◽  
Myeloablative Conditioning ◽  
Platelet Recovery ◽  
Blood Transplantation ◽  
Cell Counts ◽  
Neutrophil Engraftment

<b><i>Background:</i></b> Although the use of cord blood transplantation (CBT) is becoming more frequent in acute leukemia, considering the relationship between the low stem cell dose and graft failure, whether use of CBT for adolescents and young adults (AYAs) is appropriate remains uncertain. <b><i>Methods:</i></b> A retrospective registry-based analysis of clinical outcomes and immune reconstitution was conducted for 105 AYAs and 187 children with acute leukemia who underwent single-unit CBT using myeloablative conditioning (MAC) without antithymocyte globulin (ATG). <b><i>Results:</i></b> Outcomes were similar between AYAs and children, except for nonrelapse mortality (NRM) and recovery rates of neutrophils and platelets. The 30-day cumulative incidence of neutrophil engraftment was similar between AYAs and children, but children had faster rates of neutrophil and platelet recovery than AYAs. The median time to neutrophil engraftment was earlier in children than in AYAs (AYAs, 19 days, 95% confidence interval [CI] 17.3–21.7; children, 16 days, 95% CI 13.1–19.5, <i>p =</i> 0.00003). The incidence of platelet recovery on day 120 was higher in children than in AYAs (AYAs, 80%, 95% CI 71–81%; children, 88%, 95% CI 82–92%, <i>p =</i> 0.037). CD34<sup>+</sup> cell dose was the only independent factor influencing both neutrophil and platelet recovery. The cumulative incidence of NRM at 2 years was higher among AYAs than among children (AYAs, 27.5%, 95% CI 20–37%; children, 15%, 95% CI 10–21%, <i>p =</i> 0.008). Conditioning regimen was an independent factor influencing NRM. With respect to immune reconstitution, natural killer cell counts quickly recovered to normal levels 1-month post-CBT in both children and AYAs. CD8<sup>+</sup> T-cell counts were higher in children than in AYAs at 1 and 3 months post-CBT. CD4<sup>+</sup> T-cell counts were similar in both children and AYAs after CBT. <b><i>Conclusion:</i></b> AYAs with acute leukemia have outcomes of single-unit CBT using MAC without ATG that are as good as those of children. Thus, single-unit CBT using modified MAC without ATG is an acceptable choice for both AYAs and children who do not have a suitable donor.

Sign in / Sign up

Export Citation Format

Share Document